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INTRODUCTION: 
Sustained release drug delivery systems are designed to 
achieve a prolonged therapeutic effect by continuously 
releasing medication over an extended period of time. The 
goal in designing oral sustained or controlled delivery 
systems is to reduce the frequency of the dosing or to 
increase effectiveness of the drug by localizing at the site 
of action, reducing the dose required or provide uniform 
drug delivery, thereby also improving patient compliance. 
Sustained release dosage forms provide a better control of 
plasma drug levels, less dosage frequency, less side effect, 
increased efficacy and constant delivery.1,2 
Asthma is an extremely common disorder which affects 
many people. Asthma is viewed as an inflammatory 
condition with bronchial hyperactivity and bronchospasm. 
Continuous therapy is required for the treatment of asthma. 
Salbutamol sulphate is the drug of choice as a 
bronchodilator in the management of reversible airways 
obstruction in case of asthma and in some patients with 
chronic obstructive pulmonary disorders.3 
Salbutamol sulphate is a short acting highly selective β-2 
adrenoceptor agonist with bronchodilating property is 
widely used for the management of chronic obstructive 
pulmonary disease (COPD) which includes bronchial 
asthma, chronic bronchitis and emphysema. Salbutamol 
sulphate is almost completely absorbed from the 
gastrointestinal tract after oral administration. The reported 
plasma half-life of Salbutamol sulphate is 2.85 ± 0.85 and 
the peak plasma concentration occurs at about 30 minutes 
after an oral dose. The protein binding affinity of 
Salbutamol sulphate is 7 ± 1% and undergoes considerable 
first pass metabolism. The drug as sulphate is soluble in 1 
to 4 molar parts of water, due to the hydrophilic nature it is 
readily excreted through urine.4 Sustained release matrix 
tablets are relatively easy to fabricate by incorporating 
drug particles in slowly disintegrating or inert porous 
materials. Drug release occurs either by diffusion through 
the matrix or by erosion of the matrix or by a combination 
of both diffusion and erosion.4Oral sustained release 
dosage forms have been used to improve therapeutic 
efficacy and achieve a good patient compliance.5 
MATERIALS AND METHOD 
Salbutamol Sulphate obtained as gift sample from Shreya 
Life Sciences Pvt. Ltd. Aurangabad, HPMC K100M, 
HPMC K15M, Ethyl Cellulose, Lactose Monohydrate, 
Isopropyl Alcohol, Magnisium Stearate and Talc were of 
analytical grade. 
Experimental Work 
Sustained release matrix tablets of Salbutamol sulphate 
were prepared by wet granulation method according to the 
formula given in table. All the ingredients were passed 
through 40 mesh sieve separately. The drug and diluents 
was mixed by small portion of both each time and 
blending it to get a uniform mixture kept aside. Then add 
the isopropyl alcohol as binder then granules kept for 
drying for 1hrs at 550C then dried granules are lubricated 
with magnesium stearate and talc. Prepared granules was 
compressed (9mm FFBE Punch) using Cadmach Machine. 
Precompression Studies: 
Angle of Repose (θ):9 
The frictional forces in a loose powder can be measured by 
the angle of repose. It is an indicative of the flow 
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properties of the powder. It is defined as maximum angle 
possible between the surface of the pile of powder and the 
horizontal plane.  
θ = tan-1 (h/r) 
Where, θ is the angle of repose, h is the height in cm, r is 
the radius in cm.  
Method:  
The powder mixture was allowed to flow through the 
funnel fixed to a stand at definite height (h). The angle of 
repose was then calculated by measuring the height and 
radius of the heap of powder formed. Care was taken to 
see that the powder particles slip and roll over each other 
through the sides of the funnel.  
Bulk density:
10 
Bulk density is the ratio between a mass of granules and its 
bulk volume. It is expressed by gm/cc.  
Method:  
A bulk density (g/ml) is determined by pouring presieved 
(40 # mesh) bulk drug in to a graduated cylinder via a 
large funnel and measuring the volume and weight. 
 
Tapped Density  
Tapped density is the ratio between mass of granules and 
volume of the granules after tapping; it is expressed by 
gm/cc. 
Method:  
Tapped density is determined by placing a graduated 
cylinder containing a known mass of drug or formulation 
on a mechanical tapper apparatus, which is operated for a 
fixed number of taps (500) until the powder bed volume 
has reached a minimum. 
 
Carr’s index:11 
This was measured for the property of a powder to be 
compressed; as such they are measured for relative 
importance of interparticulate interactions. Carr’s index 
was calculated by following equation- 
 
Hausner ratio:  
Hausner ratio was calculated by following equation 
 
Where, ( ρBmax ) = tapped density, ( ρBmin ) = bulk 
density.
 
Table 1: Composition of sustained release matrix tablets of Salbutamol sulphate (Weight in mg) 
Sr. No Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 
1. Salbutamol sulphate 8 8 8 8 8 8 8 8 8 
2. HPMC K100M 40 50 60 -- -- -- -- -- -- 
3. HPMC K15M -- -- -- 40 50 60 -- -- -- 
4. Ethyl Cellulose -- -- -- -- -- -- 40 50 60 
5. Lactose Monohydrate 196 186 176 196 186 176 196 186 176 
6. Isopropyl alcohol q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
7. Magnesium stearate 4 4 4 4 4 4 4 4 4 
8. Talc 2 2 2 2 2 2 2 2 2 
9. Total weight (mg) 250 250 250 250 250 250 250 250 250 
 
Postcompression Studies: 
Tablet description:
10 
The general appearance of a tablet, its visual identity and 
overall “elegance”, is essential    for consumer acceptance. 
Thickness and diameter: 
The thickness of individual tablets was measured with a 
micrometer, which permits accurate measurement and 
provides information on the variation between tablets. The 
tablet thickness should be controlled within a ± 5% 
variation of a standard value. 
Hardness: 
Tablet required certain amount of strength, or hardness and 
resistance to friability, withstand mechanical shock of 
handling in manufacture, packaging, and shipping. Tablet 
hardness is also called as crushing strength. Monsanto 
hardness tester was used to check the hardness of the 
tablets. 
Friability: 
The friability of the tablets was measured in a Roche 
friabilator (Camp-bell Electronics, 
Mumbai, India). Tablets of a known weight (W0) or a 
sample of tablets are dedusted in a drum for a fixed time 
(100 revolutions) and weighed (W) again. Percentage 
friability was calculated from the loss in weight as given in 
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equation as below. The weight loss should not be more 
than 1%w/w.12 
% Friability = (W0-W)/ W0 × 100 
Weight Variation Test 
To study weight variation, 20 tablets of each formulation 
were weighed using an electronic balance (Electro lab, 
India), and the test was performed according to the official 
method.13 
Determination of drug contents: 
The tablets were powdered, and 8 mg equivalent weight of 
Salbutamol sulphate in tablet powder was accurately 
weighted and transferred into a 100 mL volumetric flask. 
Initially, 10 mL of phosphate buffer (pH6.8) was added 
and shaken for 10 min. then, the volume was made up to 
100 mL with buffer. Subsequently, the solution in 
volumetric flask was filtered, and 1 mL of the filtrate was 
diluted and analyzed at 276 nm using UV-visible 
spectrophotometer (Labindia). 
In vitro dissolution: 
The in vitro dissolution study was carried out using eight 
station dissolution rate test apparatus USP type-II (Basket 
type) at 50rpm. The dissolution medium consisted of 
900mL 0.1 N HCl (pH 1.2) for first 2 hrs followed by 
phosphate buffer (pH 6.8) from 2 to 12hrs. Temperature of 
the medium should maintain at 370 ±0.50 C. 
RESULTS AND DISCUSSION:
 
 
Figure 1: Standard calibration curve of Salbutamol sulphate in 0.1 N HCl (pH 1.2) 
 
Figure 2: Standard calibration curve of Salbutamol sulphate in Phosphate Buffer (pH 6.8) 
Evaluation Studies 
Table 2: Evaluation of Granules 
F Mean Angle of 
repose* ± S.D. 
Bulk density * 
(g/cc) ± S.D 
Tapped density* 
(g/cc) ± S.D. 
Compressibility 
Index* (%) ± S.D. 
Hausner’s Ratio*± 
S.D. 
F1 27
o28' ± 1.469 0.346 ± 0.0072 0.383 ± 0.0023 14.78 ± 1.547 1.138 ± 0.0197 
F2 31
o65' ± 1.118 0.341 ± 0.0043 0.384 ± 0.0024 13.15 ± 1.598 1.126 ± 0.0075 
F3 33
o26'± 1.034 0.311 ± 0.0025 0.364 ± 0.0027 9.45 ± 0.075 1.103 ± 0.0009 
F4 30
o19' ± 1.205 0.334 ± 0.0034 0.378 ± 0.0028 14.62 ± 0.292 1.118 ± 0.0036 
F5 24
o05' ± 1.259 0.335 ± 0.0018 0.377 ± 0.0031 12.01 ± 0.262 1.113 ± 0.0032 
F6 38
o65' ± 2.506 0.347 ± 0.0022 0.380 ± 0.0023 12.9 ± 0.075 1.108 ± 0.0009 
F7 31
o17'± 1.950 0.305 ± 0.0028 0.392 ± 0.0025 11.48 ± 0.192 1.139 ± 0.0025 
F8 35
o26'± 0.922 0.314 ± 0.0019 0.391 ± 0.0082 12.41 ± 1.392 1.145 ± 0.0182 
F9 30
o45' ± 1.118 0.373 ± 0.0077 0.406 ± 0.0034 11.84 ± 0.217 1.130 ± 0.0027 
*All values expressed as mean ± S.D (n=3) 
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Table 3: Evaluation of Tablets 
F Thickness (mm)# Hardness (kg/cm2)# Friability             (%)* Average Weight 
Variation (mg)#  
Drug Content 
Uniformity (%)* 
F1 5.62 ± 0.238 7.9 ± 0.418 0.14 250 ± 1.52 99.11 ± 2.01  
F2 5.64 ± 0.240 7.2 ± 1.036 0.04 249 ± 1.77 101.87 ± 3.04 
F3 5.70 ± 0.223 7.6 ± 0.651 0.012 252 ± 1.55 99.39 ± 1.31  
F4 5.72 ± 0.238 7.5 ± 0.790 0.05 250 ± 1.47 98.69 ± 1.32 
F5 5.96 ± 0.230 7.7 ± 0.570 0.17 251 ± 1.75 99.34 ± 2.01  
F6 5.52 ± 0.238 7.5 ± 0.790 0.11 250 ± 1.52 99.87 ± 2.01 
F7 5.90 ± 0.212 7.9 ± 0.651 0.06 249 ± 1.33 100.75 ± 2.73 
F8 5.90 ± 0.212 7.7 ± 0.570 0.17 251 ± 1.54 100.43 ± 2.01 
F9 5.90 ± 0.045 7.8 ± 0.836 0.08 252 ± 1.44 99.31 ± 2.35 
*All values expressed as mean ± S.D (n=3) 
#All values expressed as mean ± S.D (n=20) 
In Vitro Dissolution Study 
In-Vitro Dissolution Profile of Formulations F1-F9 %Cumulative drug release (%CDR) 
 
Figure 3: In-Vitro Dissolution Profile of Formulations F1-F3 
 
Figure 4: In-Vitro Dissolution Profile of Formulations F4-F6 
 
Figure 5: In-Vitro Dissolution Profile of Formulations F7-F9 
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KINETIC MODELING: 
Table 4: Drug release kinetics of formulations F1-F9 
Formulation Code  Zero order First order Higuchi’s Peppa’s 
R
2
 R
2
 R
2
 Slope R
2
 
F1 0.9863 0.6927 0.8846 1.4693 0.7047 
F2 0.9889 0.7304 0.8715 1.4614 0.908 
F3 0.9908 0.9292 0.8852 1.4250 0.9031 
F4 0.9956 0.8785 0.9156 1.3913 0.7911 
F5 0.9915 0.9258 0.9051 1.2472 0.7966 
F6 0.9839 0.9369 0.8667 1.3871 0.8998 
F7 0.9859 0.8934 0.8810 1.2885 0.7905 
F8 0.9884 0.9241 0.8747 1.3739 0.8974 
F9 0.9855 0.939 0.8674 1.3344 0.8925 
  
The drug release kinetics of formulations F1-F9 was obeyed 
on zero order release kinetics, as the plots showed a highest 
linearity (r
2
 = 0.9956). It can be said that the drug release 
obeying the zero order release rate kinetics is concentration 
dependent. 
SUMMARY AND CONCLUSION: 
The study was undertaken with an aim to formulation and 
evaluation of sustained release matrix tablets using various 
polymers like HPMC K100M, HPMC K15M and Ethyl 
cellulose. Lactose monohydrate used as diluents, magnesium 
sterate used as lubricant and talc was used as glidant. The 
formulations were subjected to prefomulation studies, where 
they were examined for physical mixture compatibilities 
using FTIR, where drug peaks appeared intact, indicating that 
the drug is stable. The λmax of the Salbutamol sulphate were 
found at 276 nm in two media  viz., 0.1N HCl (pH 1.2) and 
phosphate buffer (pH 6.8). Calibration curves of the pure drug 
were found using 0.1 N HCl (pH 1.2) and phosphate buffer 
(pH 6.8) by UV Spectrophotometer. The regression values 
were 0.9933 in 0.1 N HCl (pH 1.2) and 0.9939 in phosphate 
buffer (pH 6.8). The prepared granules were evaluated for 
pre-compression parameters, the results are found to be in the 
acceptable limits. Tablets were prepared by wet granulation 
method by using 9 mm round flat face beveled edges punch 
on 10 station single punch rotary tablet compression machine. 
Tablets were evaluated for post-compression parameters,  In 
vitro drug release as per official procedures. Based on the 
above study it was concluded that: Sustained release matrix 
tablets of Salbutamol sulphate were prepared using HPMC 
K100M, HPMC K15M and Ethyl cellulose as the release 
retardant polymer. The results of various evaluation 
parameters of pre-compression and post-compression studies 
of the formulations were found to be satisfactory. Among all 
the formulations prepared and evaluated, formulation F2 
containing HPMC K100M showed better release pattern in 
comparison with other formulations. By using different 
concentrations of polymers it was also possible to retard the 
release of Salbutamol sulphate upto 12 hrs. Various kinetic 
treatments of the drug release data for formulations F1 to F9 
showed that R
2
 value was highest for zero order release model 
indicating zero order drug release mechanism. Based on the 
results of the research work and the objectives envisaged in 
the research work, formulation of sustained release matrix 
tablets of Salbutamol sulphate using various polymers (i.e. 
HPMC K100M, HPMC K15M and ethyl cellulose) has been 
achieved successfully.  
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